CJC-1295 Ipamorelin pairs a long-acting GHRH analogue with the first selective growth-hormone secretagogue.

Before the details

Here is CJC-1295 Ipamorelin in plain terms. It is two research peptides used together, not one drug. CJC-1295 is a long-acting version of a natural signal called GHRH (the hormone the brain uses to tell the body to make growth hormone). Ipamorelin is a small peptide that nudges the same gland through a second, separate switch — the one the hunger hormone ghrelin uses. Because the two work through different doors, pushing both at once releases a bigger pulse of growth hormone than either does alone. People in research-use circles describe deeper sleep, faster workout recovery, and a slow lean-down over weeks. But neither peptide is approved by the FDA, and the fixed two-in-one blend has never been put through a controlled human trial — every claim about "the stack" leans on studies of each piece on its own. What people report — including the downsides like water retention and post-injection flushing — is on the effects page. The science, with sources, follows below.

What the combination is built on

The pairing rests on a simple, well-documented idea: the pituitary has two independent levers for releasing growth hormone (GH), and pulling both at once does more than pulling either alone. In normal men, submaximal doses of a growth-hormone-releasing peptide combined with GHRH stimulated GH release synergistically — the two acting through separate mechanisms ^[3]. At the receptor level, co-activating the cloned GHRH receptor and the ghrelin receptor in transfected cells produced roughly twice the cAMP signal of GHRH-receptor activation alone ^[4].

CJC-1295 supplies the GHRH arm. Ipamorelin supplies the growth hormone secretagogue arm. Their union is described here as a research combination, because that is exactly what the literature supports — and no more.

What each half has actually shown

The single-component data is real and specific. A single subcutaneous dose of CJC-1295 with DAC raised mean plasma GH two- to ten-fold for six days or more, and IGF-1 (the liver-made hormone through which GH does much of its work) 1.5- to three-fold for nine to eleven days, in healthy adults; after multiple doses IGF-1 stayed above baseline as long as 28 days ^[1].

Ipamorelin earned a distinct title: the first selective GH secretagogue. Unlike the older peptides GHRP-6 and GHRP-2, it did not raise ACTH or cortisol (stress hormones) above GHRH-stimulated levels even at doses more than 200 times the amount needed for half its GH effect, while matching GHRP-6's GH efficacy in swine ^[2]. That selectivity — a clean GH pulse without the hormonal noise — is the angle this monograph leads with. The full account, including the CJC-1295 Ipamorelin research on mechanism, sits one page over.

The honest limits, stated up front

Neither CJC-1295 nor ipamorelin is approved by the FDA for any human use; both are sold only as research chemicals. There is no peer-reviewed human pharmacology study of the pre-mixed combination itself — its claims are inferred from each compound's separate record plus the general synergy evidence ^{[3] [4]}. Both are prohibited at all times in sport under WADA Section S2 (peptide hormones and growth factors).

The combination also pairs two clocks that do not match: CJC-1295 with DAC acts over days, while ipamorelin clears within hours ^{[1] [2]}. A reader weighing the literature should hold both the promise and these gaps at once. The CJC-1295 Ipamorelin effects page lays out the reported benefits, the reported downsides, and the cited cautions in plain language, while the full CJC-1295 Ipamorelin references list carries every study cited here, with DOIs and PubMed links.